Search

Your search keyword '"Krebs, Matthew G"' showing total 173 results

Search Constraints

Start Over You searched for: Author "Krebs, Matthew G" Remove constraint Author: "Krebs, Matthew G"
173 results on '"Krebs, Matthew G"'

Search Results

2. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx

3. Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study

4. Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

5. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

6. The evolution of lung cancer and impact of subclonal selection in TRACERx

9. PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

10. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

11. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

12. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

13. Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer

14. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity

15. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

16. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

17. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

19. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

20. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK

21. Abstract CT029: Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation

22. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

23. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

24. Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA):An open-label, multicenter, phase 1/2, basket study

25. Body composition and lung cancer-associated cachexia in TRACERx

26. The evolution of non-small cell lung cancer metastases in TRACERx

27. The evolution of lung cancer and impact of subclonal selection in TRACERx

28. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

31. Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in cancers that lack known driver mutations: a case report for a cancer of unknown primary origin

32. Abstract CT201: Ceralasertib and olaparib in the treatment of homologous recombination repair (HRR)-deficient platinum-sensitive ovarian cancer after progression on PARP inhibitors

33. Abstract 2808: cfDNA multi-omics profiling and tissue of origin predictions in cancers of unknown primary

34. Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

35. Abstract CT198: Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study

36. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

37. Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

38. Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

41. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

42. Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

44. Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

45. Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC

49. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

50. EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer

Catalog

Books, media, physical & digital resources